宫内节育器：如何在分子世界中部署这一策略？
The Intrauterine Device: How to Deploy This Strategy in the Molecular World?
机构信息
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medicine, Weill Cornell Medical College, New York, New York.
出版信息
Clin Cancer Res. 2024 Nov 15;30(22):5001-5002. doi: 10.1158/1078-0432.CCR-24-2034.
Abstract
Progestin-based therapy can safely be offered to a subset of patients with atypical endometrial hyperplasia or grade 1 endometrioid endometrial cancer who desire fertility preservation. A recent study shows that levonorgestrel intrauterine device confers durable clinical benefit and identifies possible immune mechanisms of relapse and resistance. See related article by Bowen et al., p. 5073.
摘要
孕激素为基础的治疗可以安全地提供给有生育需求且希望保留生育功能的一部分非典型子宫内膜增生或低级别子宫内膜样癌患者。最近的一项研究表明，左炔诺孕酮宫内节育系统可提供持久的临床获益，并确定了复发和耐药的可能免疫机制。详见 Bowen 等人的相关文章，第 5073 页。
相似文献
1
The Intrauterine Device: How to Deploy This Strategy in the Molecular World?宫内节育器：如何在分子世界中部署这一策略？
Clin Cancer Res. 2024 Nov 15;30(22):5001-5002. doi: 10.1158/1078-0432.CCR-24-2034.
2
Fertility-preserving treatment for stage IA endometrial cancer: a systematic review and meta-analysis.保留生育功能治疗 IA 期子宫内膜癌：系统评价和荟萃分析。
Am J Obstet Gynecol. 2024 Dec;231(6):599-610.e17. doi: 10.1016/j.ajog.2024.07.018. Epub 2024 Jul 19.
3
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.前瞻性Ⅱ期临床试验：左炔诺孕酮宫内节育器在复杂性非典型增生和早期子宫内膜癌中的应用-非手术方法。
Am J Obstet Gynecol. 2021 Feb;224(2):191.e1-191.e15. doi: 10.1016/j.ajog.2020.08.032. Epub 2020 Aug 15.
4
Fertility-sparing re-treatment for endometrial cancer and atypical endometrial hyperplasia patients with progestin-resistance: a retrospective analysis of 61 cases.孕激素耐药的子宫内膜癌和不典型子宫内膜增生患者的保留生育力的再治疗：61 例回顾性分析。
World J Surg Oncol. 2024 Jun 25;22(1):169. doi: 10.1186/s12957-024-03439-w.
5
Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.口服与宫内使用孕激素对因复杂性非典型增生或子宫内膜癌接受生育力保留治疗的女性体重的影响。
Gynecol Oncol. 2016 Feb;140(2):234-8. doi: 10.1016/j.ygyno.2015.12.010. Epub 2015 Dec 17.
6
Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.孕激素治疗肥胖复杂性非典型增生妇女：左炔诺孕酮宫内节育系统与全身治疗。
Am J Obstet Gynecol. 2020 Jul;223(1):103.e1-103.e13. doi: 10.1016/j.ajog.2019.12.273. Epub 2020 Jan 21.
7
Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.是否应该评估孕激素和雌激素受体以预测子宫内膜增生和癌症保守治疗的反应？系统评价和荟萃分析。
Acta Obstet Gynecol Scand. 2019 Aug;98(8):976-987. doi: 10.1111/aogs.13586. Epub 2019 Mar 28.
8
Advanced endometrial cancer following the insertion of the levonorgestrel-releasing intrauterine system in a 34-year-old woman: A case report.34 岁女性放置左炔诺孕酮宫内缓释系统后发生晚期子宫内膜癌：病例报告。
Contraception. 2020 Dec;102(6):428-429. doi: 10.1016/j.contraception.2020.08.010. Epub 2020 Aug 27.
9
Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.孕激素治疗子宫内膜复杂不典型增生或癌的生殖和肿瘤学结局。
Am J Obstet Gynecol. 2014 Mar;210(3):255.e1-4. doi: 10.1016/j.ajog.2013.11.001. Epub 2013 Nov 8.
10
Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.促性腺激素释放激素激动剂联合左炔诺孕酮宫内节育系统或来曲唑用于年轻女性子宫内膜癌和复杂性非典型增生的生育力保留治疗
Int J Gynecol Cancer. 2017 Jul;27(6):1178-1182. doi: 10.1097/IGC.0000000000001008.
本文引用的文献
1
Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion.左炔诺孕酮宫内节育系统治疗不典型增生和早期子宫内膜癌的长期随访结果显示，复发特征为免疫衰竭。
Clin Cancer Res. 2024 Nov 15;30(22):5073-5082. doi: 10.1158/1078-0432.CCR-24-0362.
2
Molecular subtyping in endometrial cancer: A promising strategy to guide fertility preservation.子宫内膜癌的分子亚型：指导生育力保存的有前途策略。
Gynecol Oncol. 2023 Dec;179:180-187. doi: 10.1016/j.ygyno.2023.11.006. Epub 2023 Nov 21.
3
Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.整合临床测序和免疫组织化学技术对子宫内膜癌进行分子分类。
Gynecol Oncol. 2023 Jul;174:262-272. doi: 10.1016/j.ygyno.2023.05.059. Epub 2023 May 26.
4
Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium.胰岛素样生长因子I受体在增生期子宫内膜中的过表达及AKT信号通路的激活。
Clin Cancer Res. 2006 Nov 1;12(21):6373-8. doi: 10.1158/1078-0432.CCR-06-0912.
5
Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells.孕酮下调培养的人子宫平滑肌瘤细胞中胰岛素样生长因子-I的表达。
Hum Reprod. 2004 Apr;19(4):815-21. doi: 10.1093/humrep/deh146. Epub 2004 Jan 29.
6
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.色氨酸衍生的分解代谢产物负责抑制吲哚胺2,3-双加氧酶诱导的T细胞和自然杀伤细胞增殖。
J Exp Med. 2002 Aug 19;196(4):459-68. doi: 10.1084/jem.20020121.
Zotero 插件